# Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers

> **NCT02849977** · — · COMPLETED · sponsor: **Rhythm Pharmaceuticals, Inc.** · enrollment: 5966 (actual)

## Conditions studied

- Pro-opiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) and Leptin Receptor (LepR) Gene Mutations

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02849977
- **Lead sponsor:** Rhythm Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-28
- **Primary completion:** 2020-06-09
- **Final completion:** 2020-06-09
- **Target enrollment:** 5966 (ACTUAL)
- **Last updated:** 2022-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02849977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02849977, "Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02849977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*